Knowledge regarding frequent on-target resistance mutations across the ALK gene is steadily increasing.6 In their review article, Pan et al7 summarized preclinical and clinical data on the tumor-biologic effect (sensitivity versus resistance) of several on-target ALK mutations concerning approved ALK inhibitors. Here, ALK is linked to neoplasm.